🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against superbug strains of the pathogen, according to scientists.

An International Health Concern

The sexually transmitted infection are escalating around the world, with data suggesting in excess of 82 million instances per year. Notably increased rates are observed in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This milestone represents a huge turning point in the management of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

According to results published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The research included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared hope. Access to a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.